Cargando…

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

It has been recognized that the tumour markers alpha-fetoprotein (AFP) and human chorionic gonadotrophin (HCG) may show a transient elevation after the initiation of chemotherapy in non-seminomatous testicular cancer. We investigated the prognostic importance of these so-called marker surges in a co...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Wit, R., Collette, L., Sylvester, R., de Mulder, P. H., Sleijfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Stoter, G.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063177/ https://www.ncbi.nlm.nih.gov/pubmed/9823978

Ejemplares similares

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
por: de Wit, R., et al.
Publicado: (1997)

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.
por: de Wit, R., et al.
Publicado: (1998)

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.
por: de Wit, R., et al.
Publicado: (1995)

Semen quality from patients affected by seminomatous and non-seminomatous testicular tumor
por: Xavier, Rosana, et al.
Publicado: (2020)

Distinct Proteomic Profile of Spermatozoa from Men with Seminomatous and Non-Seminomatous Testicular Germ Cell Tumors
por: Panner Selvam, Manesh Kumar, et al.
Publicado: (2020)

Glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-seminomatous germ cell tumour
por: Johnson, P J, et al.
Publicado: (1999)

Compliance with follow-up of patients treated for non-seminomatous testicular cancer.
por: Young, B. J., et al.
Publicado: (1991)

A case of prostatic metastasis from non‐seminomatous testicular cancer
por: Noda, Taisho, et al.
Publicado: (2023)

Bone marrow metastasis in a patient with non‐seminomatous testicular germ cell tumor
por: Ueda, Takashi, et al.
Publicado: (2022)

The changing role of surgery in metastatic non-seminomatous germ cell tumour.
por: Cassidy, J., et al.
Publicado: (1992)

Approach to chemotherapy for high-risk, stage 1, non-seminomatous, germ cell testicular tumors
por: Anand, Madhur
Publicado: (2021)

Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors
por: Green, Daniel B., et al.
Publicado: (2021)

Case report: Challenges, treatment, prognosis and outcome of a patient with partially treated seminomatous testicular carcinoma
por: Chew, Tien Chuen, et al.
Publicado: (2021)

Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT)
por: Bono, J S de, et al.
Publicado: (2000)

A Scottish national audit of current patterns of management for patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Committee of the Royal College of Radiologists.
por: Howard, G. C., et al.
Publicado: (1995)

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
por: Hanauske, A. R., et al.
Publicado: (1996)

Testicular seminomatous mixed germ cell tumor with choriocarcinoma and teratoma with secondary somatic malignancy: a case report
por: Aneja, Amandeep, et al.
Publicado: (2014)

Testicular non-seminomatous mixed germ cell tumor with rhabdomyosarcoma and retroperitoneal metastatic mass: A case report
por: Sammour, Mohammed, et al.
Publicado: (2020)

Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma.
por: Tait, D., et al.
Publicado: (1984)

Testicular non-seminomatous germ cell tumors (NSGCT) and brain metastases: About a rare location of the posterior fossa
por: Borni, Mehdi, et al.
Publicado: (2018)

CXCL12 expression is an adverse predictor for disease recurrence in patients with metastatic non-seminomatous testicular germ cell tumors
por: Fankhauser, Christian Daniel, et al.
Publicado: (2019)

Outcome of testicular non-seminomatous germ cell tumours: report from a tertiary cancer centre in eastern India
por: Biswas, Bivas, et al.
Publicado: (2021)

Clinical characteristics of testicular non-seminomatous germ cell tumor from West China: a 10-year experience
por: Chen, Zeyu, et al.
Publicado: (2022)

Spontaneous regression as a ‘burned-out’ non-seminomatous testicular germ cell tumor: a case report and literature review
por: Dorantes-Heredia, Rita, et al.
Publicado: (2019)

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer
por: Terwogt, J M M, et al.
Publicado: (1999)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

A Scottish national mortality study assessing cause of death, quality of and variation in management of patients with testicular non-seminomatous germ-cell tumours. The Scottish Radiological Society and the Scottish Standing Committee of the Royal College of Radiologists.
por: Howard, G. C., et al.
Publicado: (1995)

Surgery in metastatic non-seminomatous germ cell tumours.
por: Tobias, J. S.
Publicado: (1992)

Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report
por: BLANCAS, ISABEL, et al.
Publicado: (2014)

Surge in testicular torsion in pediatric patients during the COVID-19 pandemic
por: Shields, Lisa B.E., et al.
Publicado: (2022)

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.
por: Dercksen, M. W., et al.
Publicado: (1993)

Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: not only a bleomycin effect.
por: Sleijfer, S., et al.
Publicado: (1995)

Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours
por: Fosså, S D, et al.
Publicado: (1999)

The management of low-stage non-seminomatous germ cell tumors
por: Lim, Louise, et al.
Publicado: (2012)

Results of treatment of non seminomatous germ cell tumours; 122 consecutive cases in the West of Scotland, 1981-1985.
por: Graham, J., et al.
Publicado: (1988)

How safe is surveillance in patients with histologically low-risk non-seminomatous testicular cancer in a geographically extended country with limited computerised tomographic resources?
por: Fosså, S. D., et al.
Publicado: (1994)

A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
por: Arends, J J, et al.
Publicado: (2005)

Non-Seminomatous Germ Cell Tumor Presenting with Superior Vena Cava Syndrome
por: Soriano, Paolo K., et al.
Publicado: (2017)

Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer
por: Olofsson, Sven-Erik, et al.
Publicado: (2015)

Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_ftm0156s86b07hr5ur6omkht24